Literature DB >> 27288455

A Drosophila model of Huntington disease-like 2 exhibits nuclear toxicity and distinct pathogenic mechanisms from Huntington disease.

Megan Krench1, Richard W Cho1,2, J Troy Littleton3,2.   

Abstract

Huntington disease-like 2 (HDL2) and Huntington disease (HD) are adult-onset neurodegenerative diseases characterized by movement disorders, psychiatric disturbances and cognitive decline. Brain tissue from HD and HDL2 patients shows degeneration of the striatum and ubiquitinated inclusions immunoreactive for polyglutamine (polyQ) antibodies. Despite these similarities, the diseases result from different genetic mutations. HD is caused by a CAG repeat expansion in the huntingtin (HTT) gene, while HDL2 results from an expansion at the junctophilin 3 (JPH3) locus. Recent evidence indicates that the HDL2 expansion may give rise to a toxic polyQ protein translated from an antisense mRNA derived from the JPH3 locus. To investigate this hypothesis, we generated and characterized a Drosophila HDL2 model and compared it with a previously established HD model. We find that neuronal expression of HDL2-Q15 is not toxic, while the expression of an expanded HDL2-Q138 protein is lethal. HDL2-Q138 forms large nuclear aggregates, with only smaller puncta observed in the cytoplasm. This is in contrast to what is observed in a Drosophila model of HD, where polyQ aggregates localize exclusively to the cytoplasm. Altering localization of HLD2 with the addition of a nuclear localization or nuclear export sequence demonstrates that nuclear accumulation is required for toxicity in the Drosophila HDL2 model. Directing HDL2-Q138 to the nucleus exacerbates toxicity in multiple tissue types, while confining HDL2-Q138 to the cytoplasm restores viability to control levels. We conclude that while HD and HDL2 have similar clinical profiles, distinct pathogenic mechanisms are likely to drive toxicity in Drosophila models of these disorders.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27288455      PMCID: PMC5179919          DOI: 10.1093/hmg/ddw166

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  91 in total

1.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

2.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

3.  Confidence intervals for predicted age of onset, given the size of (CAG)n repeat, in Huntington's disease.

Authors:  G Lucotte; J C Turpin; O Riess; J T Epplen; I Siedlaczk; F Loirat; S Hazout
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

4.  Genetic suppression of polyglutamine toxicity in Drosophila.

Authors:  P Kazemi-Esfarjani; S Benzer
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

5.  Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci.

Authors:  Dobrila D Rudnicki; Susan E Holmes; Mark W Lin; Charles A Thornton; Christopher A Ross; Russell L Margolis
Journal:  Ann Neurol       Date:  2007-03       Impact factor: 10.422

6.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

7.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

8.  SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

Authors:  E N Burright; H B Clark; A Servadio; T Matilla; R M Feddersen; W S Yunis; L A Duvick; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

9.  Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease.

Authors:  A Hodges; G Hughes; S Brooks; L Elliston; P Holmans; S B Dunnett; L Jones
Journal:  Genes Brain Behav       Date:  2007-08-13       Impact factor: 3.449

Review 10.  Polyglutamine (polyQ) disorders: the chromatin connection.

Authors:  Dorit Cohen-Carmon; Eran Meshorer
Journal:  Nucleus       Date:  2012-08-15       Impact factor: 4.197

View more
  2 in total

Review 1.  RNA toxicity and foci formation in microsatellite expansion diseases.

Authors:  Nan Zhang; Tetsuo Ashizawa
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

2.  The Drosophila junctophilin gene is functionally equivalent to its four mammalian counterparts and is a modifier of a Huntingtin poly-Q expansion and the Notch pathway.

Authors:  Eduardo Calpena; Víctor López Del Amo; Mouli Chakraborty; Beatriz Llamusí; Rubén Artero; Carmen Espinós; Máximo I Galindo
Journal:  Dis Model Mech       Date:  2018-01-17       Impact factor: 5.758

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.